BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — H1 2025 Earnings Presentation
23 slides from BTC Health Ltd Registered's earnings presentation, Feb 24, 2025
Slide 1: Investor Presentation – 1HFY25 Results
For personal use only Improving patients’ lives through global BTC Health Limited (ASX:BTC) Investor Presentation – 1HFY25 Results medical innovation February 2025
Slide 2: Disclaimer
Disclaimer Summary information This Presentation contains summary information about BTC health, and its activities current as at 24/2/2025. The information in the presentation is of a general For personal use only nature and does not purport to be complete or comprise all information which a shareho
Slide 3: Mission statement from Executive Chairman
For personal use only “Our mission is to distribute innovative and class-leading medical products, collaborating closely with healthcare professionals. By doing so, we empower patients to resume their daily passions and pursuits.” Executive Chairman Dr. Richard Treagus
Slide 4: Group structure
Group structure For personal use only BTC Health Ltd BTC Speciality BTC Cardio PL BTC Pharma PL Health PL Post-Operative Specialised Neuro-Spinal Cardio-thoracic Critical Care Pain Pharmaceuticals BTC health is a registered Pooled Development Fund (PDF) in Australia. It is a type of venture capital
Slide 5: Statutory Results – HY24 vs HY25
Statutory Results – HY24 vs HY25 For personal use only HY25 ($) HY24 ($) Interest Income 7,519 8,550 Gain on investments 5,340,505 1,963,598 Corporate Expenses (410,000) (321,265) Profit Before Tax 4,938,024 1,650,883 Profit for the Period 4,938,024 1,650,883 5
Slide 6: BTC Health and investee companies HY25 financial highlights
BTC Health and investee companies HY25 financial highlights Group Revenue* Gross Profit • YoY revenue growth, despite discontinuation of For personal use only Ambit infusion pumps. $5.3m $2.3m +6% on HY24 • Strong contribution from Cardio and ECMO +9% on HY24 products, with a $5m (5-year) Royal Chil
Slide 7: HY25 key financial metrics
HY25 key financial metrics Group Sales* Gross Proft Gross Proft Margin For personal use only $3.6M 45% $8.2M $3.3M $7.7M $7.8M $3.1M $7.2M $2.9M 43% 43% $5.3M $2.3M 40% 39% FY21 FY22 FY23 FY24 HY25 FY21 FY22 FY23 FY24 HY25 FY21 FY22 FY23 FY24 HY25 Group Operating Cost Group EBITDA EBITDA of Investee
Slide 8: Milestones achieved + delivery against goals in HY25
Milestones achieved + delivery against goals in HY25 Milestones Delivery Against Goals For personal use only $5m ECMO contract with Melbourne’s Royal Children's Hospital Disciplined cost control • BTC to supply ECMO equipment, consumables and services to Melbourne’s Royal Children’s Hospital Dou
Slide 9: Corcym Acquisition
Corcym Acquisition BTC Cardio acquires Corcym Australia/New Zealand heart valve business For personal use only • The surgical heart valve market in 2023 was estimated at $42.8m*, with approximately 5,000 surgical replacements or repairs conducted each year • Acquired Corcym’s product inventory and 3
Slide 10: Corcym Product Range
Corcym Product Range Wide range of specialised and heart valves and rings I. Perceval Plus - the only truly sutureless aortic tissue valve For personal use only II. Carbomedics mechanical heart valves for aortic and mitral valve replacement PERCEVAL PLUS III. Memo 4D mitral valve rings Strategy I. P
Slide 11: Our strategy
Our strategy For personal use only Our Advantage The Growth Opportunity • Only dedicated specialist medical • Rising consumer and government product company on the ASX. healthcare spending. • World-class capabilities, ISO 13485 • Ageing populations and rapid certification, deep industry expertise, a
Slide 12: Infrastructure and customer reach
Infrastructure and customer reach BTC health – Distribution and Sales Network Our Tier 1 Customers For personal use only Daily deliveries to 500+ hospitals (metro) and 48hr delivery (regional) 12
Slide 13: Direct access to the hospital market
Direct access to the hospital market For personal use only 1,450+ Hospitals Australasia wide Australian Market New Zealand Market Public Hospitals Public Hospitals 68% of private • 695 Public Hospitals • 84 Public Hospitals hospital funding in • $67 billion expenditure in public • $12.5 billion expe
Slide 14: Operations update
Operations update • Growth in the combined cardio and neuro-spinal business is reducing BTC’s historical reliance on infusion For personal use only pump revenue. Revenue Split - 1H FY24 Infusion Pharma Revenue Split - 1H FY25 Infusion Pumps 12% Pumps 76% 35% Pharma Cardio 12% 39% Neurospinal Cardio
Slide 15: Continuing Momentum into 2HFY25
Continuing Momentum into 2HFY25 Areas of Focus For personal use only • Winning additional ECMO hospital contracts • Increasing Perceval Plus heart valve utilisation in established centres • Expanding customer base with the neurospinal products • Converting infusion pump users across to Rhythmic and
Slide 16: Appendices
For personal use only Appendices 16
Slide 17: Post-operative pain
Post-operative pain Infusion pumps and consumables For personal use only In 2022, there were 51,894 hip replacements in Australia and 67,742 knee replacements. Both procedures involve a post-operative recovery process where an electronic, portable infusion pump is applied for acute and chronic drug
Slide 18: Neuro-spinal
Neuro-spinal IZI Medical For personal use only Innovative medical devices and single-use products used in radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures. Ilumark Products focusing on sterile single-use retro-reflective marker spheres for image-guided and
Slide 19: Cardiothoracic and critical care
Cardiothoracic and critical care CPB - Cardiopulmonary Bypass For personal use only In 2022 across public and private hospitals in Australia, there were • 12,700 coronary artery bypass graft procedures • 12,000 heart valve repair or replacement procedures, and • 129 heart transplants Each procedure
Slide 20: Cardiothoracic and critical care
Cardiothoracic and critical care PEARS BTC Cardio entered into a distribution agreement with Exstent in For personal use only FY24 to distribute its ExoVasc medical device, aka Personalised External Aortic Root Support (PEARS). 50 patients received an ExoVasc device implant in 2023, and BTC forecast
Slide 21: Heart Valves
Heart Valves AORTIC BTC Cardio entered a distribution agreement with Corcym to For personal use only distribute its sutureless Perceval Plus tissue valve and the Carbomedics mechanical valve. >300 patients received a Perceval tissue heart valve in 2024 in public and private hospitals in Australia an
Slide 22: Pharmaceutical
Pharmaceutical For personal use only Bronchitol and Aridol Bronchitol is a PBS-listed treatment for Cystic Fibrosis (CF), a disease that affects more than 3,700 people in Australia and requires ongoing treatment. Bronchitol is manufactured in Australia with BTC Pharma having acquired the exclusive A
Slide 23: Improving Australian lives through global medical innovation
Improving Australian lives through global medical innovation For personal use only For more information, please contact: BTC Health Limited Media & Investor Enquiries Dr Richard Treagus Joshua Kahanovitz Julia Maguire Executive Chairman Head of Finance The Capital Network +61 417 520 509 +61 451 321